#c. difficile cliical studies

[cdifffoundation]

Rebiotix Announces Expansion of Phase 1 Study For Prevention of Recurrent C.diff. Infection Oral Capsule Microbiota Product RBX7455

Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms Additional cohorts to examine potential of reduced dosing regimens of RBX7455 for the prevention of recurrent Clostridium difficile infection Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human…

View On WordPress

[cdifffoundation]

Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome

Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome

As published in Seres Therapeutics Press Release  January 31, 2017

  Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome –

FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109

CAMBRIDGE, Mass.,…

View On WordPress

[cdifffoundation]

Rebiotix Is Issued U.S. Patent For Its Patent Application Entitled "Microbiota Restoration Therapy (MRT) Compositions and Methods Of Manufacture"

Rebiotix Is Issued U.S. Patent For Its Patent Application Entitled “Microbiota Restoration Therapy (MRT) Compositions and Methods Of Manufacture”

Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases,  announced on October 11, 2016 that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,651 to Rebiotix for its patent application entitled, “Microbiota Restoration Therapy (MRT), Compositions and Methods of Manufacture.”Th…

View On WordPress